| Source: Research and Markets
Dublin, Oct. 12, 2020 (GLOBE NEWSWIRE) -- The "Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030" report has been added to ResearchAndMarkets.com's offering.
The 'Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030' report provides a detailed study on the current market landscape and future potential of the companies having the capabilities to manufacture radiopharmaceuticals.
According to an article published by World Nuclear Association in May 2020, more than 10,000 hospitals worldwide claim to be using radioisotopes for various medical procedures; interestingly, of the aforementioned applications, 90% were reported to be related to disease diagnosis Typically, diagnostic tests, involving radiopharmaceuticals, are performed using highly specialized imaging solutions, such as single photon emission computed tomography (SPECT) and positron emission tomography (PET).
It is worth highlighting that around 40 million diagnostic procedures, involving the use of the radioisotope Tc-99m alone, are conducted worldwide annually. Further, the introduction of the concept of theranostics, which involves the use of a single active ingredient for both diagnostic and therapeutic purposes, has opened up a new dimension of applications for nuclear medicine.
Over the years, medical research teams across the world have gradually tapped into the vast potential of radiopharmaceuticals and nuclear medicines. In fact, the technology that is now used in this field is reported to have witnessed significant evolution, in terms of technological sophistication.
As a result, the demand for such specialized chemicals has grown at an exponential rate. However, the development and production of radiopharmaceuticals is inherently complex, and requires specialized facilities and operational expertise.lucrative opportunities to the contract service providers that are engaged in this domain.
Scope Of the Report
- A detailed assessment of the current market landscape with respect to the players (industry and non-industry) involved in manufacturing radiopharmaceuticals. It features information on the year of establishment, company size, purpose of production (fulfilling in-house requirements / for contract services), location of headquarters, location of manufacturing facilities, scale of production, applications of radiopharmaceuticals (in diagnosis, therapeutics and theranostics), type of diagnostic radiopharmaceuticals (PET and SPECT), type of therapeutic radiopharmaceuticals (alpha emitters, beta emitters and others), target therapeutic area (cardiology, oncology, neurology, thyroid and others) and services offered.
- An insightful four-dimensional comparison of the radiopharmaceutical manufacturers, based on supplier power (year of establishment), product portfolio (number of isotopes being manufactured for various applications targeting different therapeutic areas) of the manufacturer, scale at which they manufacture their respective products and company size.
- Tabulated profiles of key industry players based in North America, Europe and Asia-Pacific (shortlisted based on the company size of the players), featuring a brief overview of the company, a list of products and manufacturing facilities, recent developments and an informed future outlook.
- An analysis of recent partnerships and collaborations inked in this domain since 2017, based on several parameters, such as the type of partnership, year of partnership, type of radioisotope involved, therapeutic area mentioned in the agreement, application of the radioisotope mentioned in the agreement, and a schematic representation showcasing the players that have forged the maximum number of alliances. Furthermore, we have provided a world map representation of the deals inked in this field, highlighting those that have been established within and across different continents.
- A detailed discussion on the supply chain model of medical isotope Mo-99 (Tc-99m), highlighting the main steps of the supply chain, from irradiation of uranium targets in nuclear research reactors to the administration of Tc-99m to patients. Along with this, it describes the structure of the industry and product market at each step.
Key Questions Answered
- Who are the leading industry and non-industry players engaged in the nuclear medicine and radiopharmaceutical manufacturing market?
- For which application and disease indications are the radiopharmaceuticals being manufactured?
- What are the various type of radionuclides being manufactured for the formulation of radiopharmaceuticals?
- What is the relative competitiveness of manufacturers involved in the nuclear medicine and radiopharmaceutical manufacturing?
- Which partnership models are commonly adopted by the radiopharmaceutical manufacturers in this industry?
- What is the supply chain process for medical isotope Mo-99 / Tc-99m?
- What are the key factors that are likely to influence the evolution of the nuclear medicine and radiopharmaceutical manufacturing market?
- How is the current and future market opportunity likely to be distributed across key market segments?
Companies Mentioned
- 3D Imaging Drug Design and Development
- ABX advanced biochemical compounds
- Abzena
- Advanced Accelerator Applications
- Advanced Nuclear Medicine Ingredients
- Ahmanson Translational Imaging Division
- Alliance Medical
- Alpha Tau
- Arronax
- ARTMS Products
- ASAN Medical Center
- Atlab Pharma
- ATONCO
- Australian Nuclear Science and Technology Organisation
- Avid Radiopharmaceuticals
- Bar-Ilan University
- Bayer
- Biomedical Research Imaging Center, UNC School of Medicine
- Bio-Nucleonics
- Blue Earth Diagnostics
- Board of Radiation and Isotope Technology
- Bracco Diagnostics
- Bruce Power
- BWX Technologies
- Cameco
- Canadian Nuclear Isotope Council
- Cancer Targeted Technology
- Cardinal Health
- Center for Molecular and Genomic Imaging, UC Davis
- Center for Neurosciences, The Feinstein Institute
- Center for Radiochemistry Research, OHSU Knight Cardiovascular Institute
- Center for Systems Imaging Core, Emory University
- Centre for Advanced Imaging, The University of Queensland
- Centre for In Vivo Imaging, Newcastle University
- Centre for Probe Development and Commercialization
- Cerveau Technologies
- Chengdu Gaotong Isotope
- Chengdu New Radiomedicine Technology
- China Isotope & Radiation Corporation
- Clinical Imaging Research Centre, National University of Singapore
- Crump Cyclotron and Radiochemistry Technology Center,University of California
- Curium Pharma
- Cyclopharma
- Cyclotek
- Cyclotope Radiopharmacy
- Cyclotron & Radiochemistry Facility, Stanford University School of Medicine
- Cyclotron and Radiochemistry Facility, Citigroup Biomedical Imaging Center of Weill Cornell Medicine
- Cyclotron and Radiochemistry Facility, UT Southwestern Medical Center
- Cyclotron and Radiochemistry Laboratories, Keck School of Medicine of USC
- Cyclotron and Radiopharmaceutical Core, Houston Methodist Research Institute
- Cyclotron and Radiopharmaceuticals Department, King Faisal Specialist Hospital and Research Centre
- Cyclotron Facility, University of Chicago
- Cyclotron Radiochemistry Facility, MD Anderson Cancer Center
- Department of Molecular and Medical Pharmacology, University of California
- Department of Nuclear Medicine and PET, Liverpool Hospital
- Department of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine
- Department of Nuclear Medicine, School of Health Sciences, University of Ioannina
- Department of Radiology & Biomedical Imaging, University of California
- Department of Radiology, The University of Alabama at Birmingham
- Department of Radiology, University of Colorado
- Department of Radioplogy, Penn Medicine, University of Pennsylvania
- Dongcheng Biochemicals
- DuChemBio
- Eckert & Ziegler
- Eczacibasi-Monrol
- Endocyte
- Essential Isotopes
- Framatome
- FUJIFILM Toyama Chemical
- FutureChem
- GE Healthcare
- GE Hitachi Nuclear Energy
- Global Medical Solutions
- Global Morpho Pharma
- Grupo RPH
- HealthTrust
- Heidelberg Pharma
- Heidelberg University Hospital
- Huntsman Cancer Institute Center for Quantitative Cancer Imaging, Univeristy of Utah Health
- IASON
- ImaginAb
- Imaging Facilities, The University of Manchester
- Inserm
- Institut National des Radioelements
- Institute for Energy Technology
- Institute of Applied Radiopharmacy of Barcelona
- Institute of Isotopes (IZOTOP)
- Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf
- International Isotopes
- IRE ELiT- Radiopharmaceuticals
- Iso-Tex Diagnostics
- IsoTherapeutics
- Isotopia Molecular Imaging
- Itelpharma
- iThemba LABS
- ITM Isotopen Technologien Munchen
- Jubilant Radiopharma
- Kinectrics
- Korea Insititute of Radiological & Medical Sciences
- Kresge Cyclotron/PET Facility, Department of Radiology, University of Michigan
- Lantheus Medical Imaging
- Life Molecular Imaging
- Macquarie University
- Mallinckrodt Institute of Radiology, PET Nuclear Pharmacy and Cyclotron Facility, Washington University
- Mallinckrodt Nuclear Imaging
- Map Medical Technologies
- Mayo Clinic
- McMaster University Cyclotron Facility
- Medi-Radiopharma
- Memorial Sloan Kettering Cancer Center
- Merck
- Micro-Rad
- Molecular Imaging Institute (M2i)
- NanoMab Technology
- National Centre for Nuclear Research Radioisotope Centre (POLATOM)
- NCMUSA
- Nihon Medi-Physics
- Ningbo Junan Pharmaceuticals Technology
- Nordal Cyclotron & PET Radiochemistry, Lawson Health Research Institute
- Nordic Nanovector
- Nordion
- Norsk Medisinsk
- Novartis
- NTP Radioisotopes
- Nuclear and Energy Research Institute
- Nuclear Medicine and Molecular Imaging, University of Groningen
- Nuclear Medicine/Biomedical Imaging Research Core, Brigham and Women's Hospital
- Nuclear Research Institute Rez
- Nucleis Radiopharmaceuticals
- OncoBeta
- Ontario Power Generation
- PET Center, Columbia University
- PET Core, Gordan Center for Medical Imaging, Harvard Medical School
- PET Pharm Biotech
- PET Radiochemistry and Radiopharmacy, University of Oxford
- PET Research Core, Renaissance School of Medicine, Stony Brook University
- PET Research Facility, Wake Forest School of Medicine
- PET Research Radiochemistry, University of Ottawa
- PETNET Solutions
- PetTecH Solutions
- Piramal Imaging
- PositronPharma
- Premier
- Progenics Pharmaceuticals
- Q BioMed
- Radboud University Medical Center
- Radiochemistry & Molecular Imaging Probes Core Facility, Memorial Sloan Kettering Cancer Center
- Radiochemistry Core, University of Virginia
- Radiochemistry Core, Vanderbilt University Institute of Imaging Science
- Radiochemistry Facility, Loma Linda University
- Radiochemistry Unit, University of Helsinki
- RadioMedix
- Radiopharmaceutical Core Facility, Case Western Reserve University
- Radiopharmazeutische Wissenschaften, Division of Nuclear Medicine at the Medical University of Vienna
- RadLink Asia
- Research Imaging Institute, University of Teaxs Health Science Center
- Rosatom State Atomic Energy Corporation
- ROTOP Pharmaka
- Saskatchewan Centre for Cyclotron Sciences
- SCK.CEN
- Seibersdorf Laboratories
- Shertech Nuclear
- Sinotau Pharmaceutical
- Societatea Nationala Nuclearelectrica
- SOFIE
- SpectronRx
- SWAN Isotopen
- Techna Institute
- Telix Pharmaceuticals
- The McConnell Brain Imaging Centre, University of McGrill
- Theragnostics
- Therapeia
- Thunder Bay Cyclotron and Radiochemistry Laboratories, Lakehead University
- Tong Xing
- Toyama Chemical
- Triad Isotopes
- Turku PET Centre
- United Imaging Healthcare
- University of Melbourne
- University of Missouri
- University of Washington Radiochemistry Resources
- USC Molecular Imaging Center, University of Southern California
- Vect-Horus
- Westinghouse Partners
- Wolfson Brain Imaging Centre, University of Cambridge
- Xcision
- Y-mAbs Therapeutics
- Zevacor Molecular
- Zionexa
For more information about this report visit https://www.researchandmarkets.com/r/a8i3ry
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Subscribe via RSS
Dublin, IRELAND
